Breakthrough in Bacterial Cancer Therapy

A research team led by Professor Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST), in collaboration with Daiichi sankyo Co., Ltd. and the University of Tsukuba, has created an innovative cancer treatment that works without relying on the immune system. The new approach uses a unique microbial partnership known as AUN, forming the foundation of an immune-independent bacterial therapy.

The concept of bacterial cancer therapy dates back to 1868, when German physician Busch reported that a cancer patient deliberately infected with bacteria later experienced remission. In 1893, Dr. William Coley further advanced this idea by developing what became known as Coley’s toxins, mixtures of bacteria used to stimulate the immune system to fight cancer. Coley’s toxins represented an early, albeit crude, attempt at harnessing the power of bacteria in cancer treatment.

Though, these early methods relied heavily on a functioning immune system. Professor Miyako’s team’s innovation lies in bypassing this requirement. Their approach centers on the Japanese concept of “AUN,” symbolizing balance and harmony between opposites. It is this finely tuned relationship that gives the therapy its exceptional results,achieving what traditional immune-dependent treatments could not.

the AUN Principle and Microbial Partnership

The AUN principle, central to this therapy, emphasizes the synergistic relationship between two bacterial species. While the specific species involved haven’t been publicly disclosed beyond being described as a “unique microbial partnership,” the researchers explain that their combined action directly targets and destroys cancer cells without triggering an immune response. This is a critical distinction from existing immunotherapies, which rely on activating the patient’s own immune system to recognize and attack cancer cells.

This immune-independent mechanism is particularly promising for patients undergoing chemotherapy or radiation, or those with pre-existing immune deficiencies, where conventional immunotherapies are frequently enough less effective or carry significant risks. The therapy’s ability to function *without* immune involvement opens up treatment possibilities for a wider range of patients.

Toward Clinical Trials and a New Era

“We are preparing to launch a startup to advance this technology and hope to begin clinical trials within six years,” explained Professor Miyako. “A new chapter in bacteria-based cancer therapy — pursued for over 150 years — is finally beginning.”

This groundbreaking method marks a turning point for cancer patients with weakened immune systems. It offers a long-sought option where conventional immunotherapies fall short,signaling the arrival of truly immune-independent cancer treatment.